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Introduction: Electronic brachytherapy (EBT) was developed to allow accelerated partial 
breast irradiation to be performed in a patient procedure room with minimal shielding. This 
observational, nonrandomized, multicenter study evaluated EBT as a post-surgical adjuvant 
radiation therapy for early stage breast cancer.
Methods: This study included women aged 50 years or more with invasive carcinoma or ductal 
carcinoma in situ, tumor size #3 cm, negative lymph node status, and negative surgical margins. 
The endpoints were skin and subcutaneous toxicities, efficacy outcomes, cosmetic outcomes, 
and device performance. In this interim report, 1-month, 6-month, and 1-year follow-up data 
are available on 68, 59, and 37 patients, respectively.
Results: The EBT device performed consistently, delivering the prescribed 34 Gy to all 69 
patients (10 fractions/patient). Most adverse events were Grade 1 and included firmness, 
  erythema, breast tenderness, hyperpigmentation, pruritis, field contracture, seroma, rash/desqua-
mation, palpable mass, breast edema, hypopigmentation, telangiectasia, and blistering, which 
were anticipated. Breast infection occurred in two (2.9%) patients. No tumor recurrences were 
reported. Cosmetic outcomes were excellent or good in 83.9%–100% of evaluable patients at 
1 month, 6 months, and 1 year.
Conclusion: This observational, nonrandomized, multicenter study demonstrates that this 
EBT device was reliable and well tolerated as an adjuvant radiation therapy for early stage 
breast cancer.
Keywords: radiation therapy, electronic brachytherapy, breast cancer
Introduction
An estimated 254,650 new cases of breast cancer were diagnosed in 2009.1 Breast 
conserving therapy (BCT) for patients with stage I or II breast cancer consists of sur-
gical removal of the tumor with negative margins and axillary sentinel lymph node 
dissection followed by radiation therapy to further decrease the chance of a recurrence. 
Several studies have shown BCT to be comparable to mastectomy in terms of overall 
and disease-free survival for patients.2–7 The major advantage of BCT over mastec-
tomy is cosmetic outcome and reduced psychological trauma to the patient. The major 
disadvantage to BCT is the prolonged time of radiation treatment. The whole breast 
radiation portion of BCT can add 7 weeks to the treatment time, which prevents some 
women from choosing BCT, particularly if substantial travel time is required to reach 
the radiation treatment facility.8–10
Accelerated partial breast irradiation (APBI) was developed to decrease expo-
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breast irradiation from 7 weeks to 1 week.10 The method of 
breast brachytherapy with the longest reported follow-up 
is multicatheter interstitial brachytherapy. This technique 
utilizes up to 20 catheters placed through and around the 
lumpectomy bed to allow delivery of the radiation seed 
to the target area around the breast cavity. Several studies 
utilizing this technique have reported favorable cosmesis 
and rates of local control.11–13 However, even using the best 
imaging available, the technique requires a great deal of 
experience and skill to position the 20 catheters to cover 
the required treatment area and is only offered at a few 
institutions around the country. Other devices have been 
developed to provide a logistically simpler technique for 
APBI, and data on local control, toxicity, and cosmesis 
have been favorable.14–16 However, these techniques rely 
on a 192Iridium source, which requires a radiation vault and 
high-dose-rate (HDR) afterloader unit, which many treat-
ment centers do not have.17
An electronic form of brachytherapy (EBT) was devel-
oped to allow APBI to be performed in a patient procedure 
room with minimal shielding.17–19 This device (Axxent®; 
Xoft, Inc., Sunnyvale, CA) uses a kilovoltage X-ray source 
to deliver HDR radiation to the tumor bed through a balloon 
applicator (Figure 1). One-year follow-up data from a multi-
center study demonstrated control rates, cosmesis, and toler-
ability similar to other forms of breast brachytherapy.20 This 
form of brachytherapy has been shown in dosimetric studies 
to deliver lower doses of radiation to the heart and lung 
compared with 192Iridium-based balloon brachytherapy.17,21 
In addition, electronic source anisotropy and multiple dwell 
positions obtainable with this device may allow a decreased 
skin dose while maintaining optimal target coverage.22 
A kilovoltage brachytherapy approach has the potential to 
allow APBI to be more accessible to breast cancer patients 
who do not live in close proximity to a radiation treatment 
facility with an HDR afterloader unit. This observational, 
nonrandomized, multicenter, data collection study was 
designed to prospectively evaluate the safety and efficacy of 
EBT as a post-surgical adjuvant radiation therapy for early 
stage breast cancer.
Methods
The study protocol was developed under the guidance of the 
American Brachytherapy Society (ABS), the American Soci-
ety of Breast Surgeons (ASBS), and the American College 
of Radiation Oncology (ACRO). Representatives from these 
three organizations formed an oversight committee, which 
was responsible for finalization of the protocol and case 
report forms as well as oversight of the study management. 
An independent data safety monitoring board comprised of 
representatives from the ABS, ASBS, and ACRO reviewed 
and adjudicated the safety data at least quarterly.
The protocol and informed consent form were approved 
by an institutional review board for each site that participated 
in the study. Patients signed an informed consent form prior to 
study entry. The study was conducted in accordance with the 
Declaration of Helsinki and all applicable regulations. The 
study sponsor (Xoft, Inc.) selected the investigators, study 
centers, and monitors, provided study training to investiga-
tors and study staff, and reviewed study implementation 
regularly to ensure protocol and regulatory compliance as 
well as adherence to good clinical practices. The clinical 
study sites provided all contact with health care services for 
patients and entered the data on electronic case report forms 
in an electronic data capture (EDC) system. The EDC stan-
dards are compliant with the United States Food and Drug 
Administration (FDA) federal regulations for electronic 
records and electronic signatures, which utilizes unique user 
names, passwords, and audit trails for data entry and edits. 
The study monitors performed source data verification and 
ensured protocol compliance. An independent biostatistician 
performed the data analyses.
Patients
Patients had to be 50 years of age or older, be estrogen-  receptor 
positive, have a tumor size #3 cm, have a tumor histology 
consistent with invasive carcinoma or ductal carcinoma in situ, 
be sentinel lymph node negative with negative surgical mar-
gins (National Surgical Adjuvant Breast and Bowel   Project 
definition, no tumor on ink) after final surgery, and have a 
life expectancy .5 years. Patients were excluded if they were 
pregnant or breastfeeding, were not using birth control, had 
collagen vascular disease (including scleroderma, systemic 
sclerosis, or active lupus), had infiltrating lobular histology, 
or had prior ipsilateral radiation to the thorax or breast. Figure 1 electronic source.OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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A post-lumpectomy ultrasound (US) or computed tomog-
raphy (CT) was used to properly assess each patient’s eligi-
bility for balloon applicator placement. CT was the ultimate 
determinant for assessing adequate skin spacing following 
balloon applicator insertion.
Materials
The FDA-cleared EBT system consists of the kilovoltage 
X-ray source, the mobile controller, and the balloon applica-
tors. The balloon applicator is used to position tissue and an 
electronic source during breast brachytherapy treatments. 
The applicator consists of a multilumen catheter with an 
inflatable balloon assembly at its distal end. The applicators 
are available in an ellipsoidal shape or in three sizes of a 
spherical shape, all with variable diameters. The Model 110 
controller provides the user interface, monitors safety-related 
parameters, provides an interface for the external equipment, 
and delivers power to the X-ray source. The X-ray source 
pullback device on the controller is used to physically trans-
late the source to specific dwell positions during radiation 
treatment. The source delivers HDR, low-energy radiation by 
generating 50 kilovolt X-rays without the use of radioactive 
isotopes. The source has a radiation profile that is character-
ized according to the American Association of Physicists in 
Medicine TG-43 format.23 Air kerma strength for the source 
was measured using an integrated well ionization chamber 
prior to the delivery of each fraction of radiation.
Device placement
Following standard lumpectomy surgery and confirmation of 
pathology results, an EBT balloon applicator was selected to 
best fit the tumor cavity. The balloon applicator was placed 
following a closed cavity placement technique only. The use 
of cavity expander/space-occupying devices was permitted 
as determined to be appropriate by the physician. The bal-
loon applicator was inflated with saline to fill the cavity at 
the time of placement and remained inflated throughout the 
5-day treatment period.
Treatment
A total of 34 Gy was prescribed to 10 mm distance radially 
from the surface of the balloon. Two fractions per day, each 
3.4 Gy, separated by at least 6 hours were to be administered 
over 5 treatment days for a total of 34 Gy. Balloon place-
ment, conformance, and skin distance were assessed prior to 
each fraction using US, fluoroscopy, or CT for a total of 10 
assessments. In particular, the balloon applicator was veri-
fied to be symmetrical with the central source lumen within 
2 mm of the central axis of the balloon. All nonconforming 
volumes such as trapped air and/or seroma had to be #10% 
of the planning target volume for evaluation (PTV_EVAL). 
The applicator was removed using standard sterile techniques 
after the completion of the final EBT fraction.
A US image was required at each follow-up visit in accor-
dance with the local standard of care. A mammogram was 
required based on standard practice after BCT and to assist 
in the diagnosis of subcutaneous toxicities. Patient follow-up 
visits were scheduled to occur at 1 month, 6 months, 1 year, 
2 years, 3 years, 4 years, and 5 years post-treatment.
Treatment planning
A CT was required for three-dimensional (3D) treatment 
planning following balloon applicator placement. Treatment 
planning was performed on commercially available radiation 
treatment planning systems such as Varian BrachyVision™ 
or Nucletron PLATO. CT data acquisition with 3.0 mm slices 
or less was required. Source location, number of positions, 
and dwell times were at the discretion of the physician and 
were determined by CT-based 3D treatment planning to pro-
duce the optimal conformal plan in accordance with volume 
definition and dose requirements. The treatment plan used 
for each patient was based on analysis of the   volumetric 
dose including dose-volume histogram analyses of the 
PTV_EVAL and critical normal tissues. The treatment target 
was the breast tissue immediately surrounding the balloon 
to a measured distance of 10 mm from the balloon surface. 
The PTV_EVAL was delineated as the breast tissue volume 
bounded by the uniform expansion of the balloon radius in 
all dimensions by 10 mm minus the balloon volume.
Primary endpoints
The incidence of signs and symptoms of skin toxicities and 
subcutaneous toxicities were recorded at the follow-up visits. 
Specific toxicities that can result from radiation therapy and 
any other adverse events were recorded at the follow-up 
  visits. The Common Terminology Criteria for Adverse 
Events version 3 were used.24
Cosmetic outcome was recorded at the follow-up visits 
and was graded based on the Harvard Cosmesis Scale by a 
health care professional.25 This four-point scale includes rat-
ings of excellent (treated breast looks essentially the same as 
the opposite breast), good (minimal but identifiable effects 
of radiation procedure on the treated breast), fair (significant 
effects of radiation procedure on the treated breast), and 
poor (severe normal tissue sequelae secondary to irradiation 
procedure).OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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secondary endpoints
Device performance during balloon applicator placement 
and the course of the radiation treatments was evaluated in 
terms of the ability to deliver treatment and performance 
of the system and applicator. Local-regional breast cancer 
recurrence and survival (overall and disease free) were also 
recorded at each follow-up visit.
statistical analyses
Descriptive statistics were reported as the number (n), mean, 
minimum, and maximum for continuous variables. For nomi-
nal variables, the n and proportion for each category were 
reported. A Wilcoxon two-sample t-test was used to evaluate 
the association of cosmesis and balloon volume or balloon-
surface-to-skin distance. A chi-square was used to evaluate 
the association of cosmesis and the rate of adverse events.
Results
The study included 69 female patients as summarized in 
Table 1. Tumor characteristics at the time of surgery are 
summarized in Table 2. Most patients (75.4%) did not have a 
family history of breast cancer. This interim analysis reports 
the duration of follow-up for the patients through May 31, 
2010. Of the 69 enrolled and treated, 68 have been evaluated 
at 1 month, 59 patients at 6 months, and 37 patients at 1 year of 
follow-up. In addition to the 69 patients who were treated, eight 
patients underwent balloon insertion and did not proceed to 
radiation therapy due to inadequate distance from the balloon 
surface to the skin in six patients or inadequate distance from 
the rib in two patients. One additional patient who consented 
to the treatment experienced a myocardial infarction (MI) and 
did not proceed with balloon insertion due to the MI.
The applicator was placed post-lumpectomy by a surgeon 
in 66 (95.7%) patients and by a radiation oncologist in two 
(2.9%) patients; the applicator was placed at the time of 
lumpectomy in the operating room by both the surgeon and 
the radiation oncologist in one patient (1.4%). The procedure 
took place in a procedure room in 65 (94.2%) patients and 
in an operating room or elsewhere in four (5.8%) patients. 
Sedation was provided for 22 (31.9%) patients, and local 
anesthesia was administered to 67 (97.1%) patients. The 
procedure lasted a mean duration of 24.3 minutes and ranged 
from 4.0 to 69.0 minutes. In most cases a trocar was used 
(95.6%) with a lateral approach (84.1%). Surgical clips were 
present in 33.3% of cases. Most patients (95.7%) underwent 
US assessment of the distance from the balloon surface to 
the skin surface at the time of applicator placement, and 
the mean distance was 12.8 mm (range 7.0–22.0 mm). One 
patient was not assessed, and two patients, who underwent 
CT scans at the time of applicator placement, had mean 
distances of 6.8 mm and 18.0 mm. The mean volume of 
fluid used to inflate the balloon applicators was 56.8 mL and 
ranged from 30.0 to 140.0 mL. Spherical balloon applicators 
of size 3–4 cm, 4–5 cm, and 5–6 cm were used in 17 (24.6%), 
39 (56.5%), and 12 (17.4%) patients, respectively. The 
5 × 7 cm ellipsoidal balloon applicator was used in one 
(1.5%) patient (Table 3). Three balloon deflations occurred 
at the time of placement due to contact with a sharp object; 
Table 1 Patient characteristics at baseline
number of patients 69
Mean age in years (range) 67.5 (43.4–85.3)
Female 69 (100%)
Menopausal status
  Post-menopausal 64 (92.7%)
  Peri-menopausal 2 (2.9%)
  Pre-menopausal 3 (4.4%)
race
  caucasian 54 (78.3%)
  African-American 13 (18.8%)
  hispanic 1 (1.5%)
  Asian 1 (1.5%)
Table 2 Tumor characteristics at baseline
Tumor size (mean and range) 
n = 65a
1.2 (0.1–3.0) cm
initial volume of excised tissue 
(mean and range) 
161.6 (7.20–690.00) mL
Tumor characteristics in all patients 69 (100%)
AJcc class
  Tis 20 (29.0%)
  T1a 8 (11.6%)
  T1b 18 (26.1%)
  T1c 20 (29.0%)
  T2 3 (4.4%)
histopathologic grade
  grade 1 well differentiated 19 (27.5%)
  grade 2 moderately differentiated 21 (30.4%)
  grade 3 poorly differentiated 12 (17.4%)
  grade not available 17 (24.6%)
Lesion location (side)
  Left side 42 (60.9%)
  right side 27 (39.1%)
Lesion location (vertical)
  Upper 44 (63.8%)
  Lower 8 (11.6%)
  Midline 17 (24.6%)
Lesion location (horizontal)
  Outer 38 (55.1%)
  inner 15 (21.7%)
  Midline 16 (23.2%)
Note:   aTumor size not recorded in the medical chart of four Dcis patients.
Abbreviation: AJcc, American Joint committee on cancer.OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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the balloon applicators were replaced, and treatment was 
completed. One patient reported breast tenderness at the 
time of placement; no other adverse events were reported 
at the placement visit.
The prescribed radiation dose was 34 Gy, to be delivered 
in 10 fractions over 5 days in all 69 patients. The prescribed 
fractional radiation dose of 3.4 Gy was successfully deliv-
ered in 688 of 690 fractions (99.7%) with 3.3 Gy and 3.5 Gy 
delivered in 2 of 690 fractions (0.3%). All patients received 
34 Gy over 10 fractions. The skin bridge was evaluated by CT 
prior to treatment; the mean minimum balloon-to-skin   surface 
distance was 15.5 mm and ranged from 5.5 to 42.0 mm. The 
mean planning treatment volume was 110.2 mL and ranged 
from 35.0 to 192.0 mL. Erythema was reported in three 
patients during a treatment visit; no other adverse events 
were reported at treatment visits. A technical difficulty arose 
with the X-ray sources during 17 of 690 (2.5%) fractions. 
This was due to a source arc, which occurs when the vacuum 
chamber at the tip of the treatment catheter has a very small 
electrical discharge resulting in a voltage reduction from 
50 kilovolts to ground. This occurs inside the grounded tube 
and does not affect the patient. The device controller has an 
automatic detection function, which prompts the operator 
to replace the source, which results in a 5–10 minute delay. 
In each case, the source was replaced, and treatment was 
completed. Controller issues, which related to the pullback 
mechanism or coolant flow in the applicator, arose during 
3 of 690 (0.4%) fractions; these issues were addressed, and 
treatments were completed. After each patient completed 10 
fractional treatments, the balloon applicator was removed, 
typically in a procedure room (68.5%).
Adverse events were collected at each follow-up visit. 
Most treatment-related adverse events were Grade 1, manage-
able, and typical of radiation therapy (Table 4). There were 
29 Grade 2 adverse events in 15 patients, and 19 of the 29 
(65.5%) events occurred at one month (Table 5). Two patients 
Table 3 Applicator sizes used and respective saline volumes
Applicator sizes used and saline instilled (0.9NS) in mL
Final applicator model
Balloon  
applicator 
diameters
3–4 cm 
spherical
4–5 cm 
spherical
5–6 cm 
spherical
5 × 7 cm 
ellipsoidal
n 17 39 12 1
Mean (mL) 36.47 53.41 89.58 140.00
std Dev (mL) 6.06 9.38 21.37 –
Min (mL) 30.00 30.00 60.00 140.00
Max (mL) 45.00 75.00 130.00 140.00
Abbreviations: ns, normal saline; std Dev, standard deviation; Min, minimum; 
Max, maximum.
Table  4  grade  1  adverse  events.  Adverse  events  that  were 
possibly, probably, or definitely related to applicator placement 
or radiation therapy as reported at each follow-up visit unless 
otherwise noted
Grade 1 events 1 month 6 months 1 year
number of patients 68a 59 37
Induration/firmness-slight 25 (36.8%)b 14 (23.7%) 5 (13.5%)
erythema 27 (39.7%)c 1 (1.7%) 1 (2.7%)
Breast tenderness 14 (20.6%)d 11 (18.6%) 4 (10.8%)
hyperpigmentation 14 (20.6%) 6 (10.2%) 2 (5.4%)
Pruritis 14 (20.6%) 2 (3.4%) 1 (2.7%)
Field contracture-slight  
indent in skin
7 (10.3%) 6 (10.2%)e 2 (5.4%)
seroma 8 (11.8%) 4 (6.8%) 4 (10.8%)
rash/desquamation-dry 9 (13.2%) 0 0
Palpable mass 3 (4.4%)e 2 (3.4%) 4 (10.8%)
rash/desquamation-moist 6 (8.8%) 0 0
Breast edema 3 (4.4%) 1 (1.7%) 1 (2.7%)
infection 0 1 (1.7%) 0
Loss of subcutaneous  
tissue on palpation
1 (1.5%) 1 (1.7%) 1 (2.7%)
Atrophy-slight  2 (2.9%) 0 1 (2.7%)
hypopigmentation 1 (1.5%) 2 (3.4%) 1 (2.7%)
Telangiectasia 2 (2.9%) 1 (1.7%) 0
Lymphedema  0 2 (3.4%) 0
Pigmentation change (1.5%) 0 0
Bleeding at treated site 1 (1.5%) 0 0
Blistering 1 (1.5%) 0 0
skin thickening 0 1 (1.7%) 0
Wound dehiscence  
(wound complication – 
noninfection)
1 (1.4%) 0 0
Notes:   aOne of the 69 treated patients did not complete the 1-month follow-up visit 
due to an acute myocardial infarction and subsequent death; no treatment-related 
adverse events occurred in this patient; bincludes one unscheduled visit around 1 
month post-treatment; cincludes three treatment visits and one unscheduled visit 
around 1 month; dincludes two unscheduled visits around 1 month post-treatment 
and  one  Balloon  Applicator  insertion  visit;  eincludes  one  occurrence  in  the 
nontreated breast; fincludes one with an indurated scar.
reported one or more adverse events that were assessed as 
Grade 3 by the physician (Table 5). One patient had diarrhea 
related to Clostridium difficile infection resulting from pro-
phylactic antibiotic use and a significant field contracture both 
at 1 month post treatment. The other patient had a fibrosis of 
connective tissue at 1 year post-treatment that the investigator 
deemed to be possibly related to treatment. No recurrences 
were reported, and there were no deaths due to cancer. One 
patient experienced an acute myocardial infarction when 
1-month follow-up was due and later expired.
Cosmetic results were evaluated by the investigator as 
excellent, good, fair, or poor at each visit based on the Har-
vard Scale.25 Cosmesis was excellent or good (minimal or no 
identifiable effects of radiation) in 83.9%, 84.5%, and 100% 
of evaluable patients at 1 month, 6 months, and 1 year. An 
analysis of cosmetic results revealed an association between OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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fair or poor cosmesis and an increased rate of visible adverse 
events (erythema, rash, field contracture, pigmentation 
changes, and other visible effects) at 6 months (P = 0.04) 
but not at 1 month. Further analysis showed that the 6-month 
cosmetic results were not associated with balloon volume 
or the distance from the balloon surface to the skin prior to 
treatment.
Discussion
This observational, nonrandomized, multicenter study was 
undertaken following FDA clearance of the EBT device 
in order to better understand the clinical use of EBT as an 
adjuvant radiation therapy for early stage breast cancer. Rep-
resentatives from the ABS, the ASBS, and the ACRO guided 
protocol development, study conduct, and data analyses. 
The prospectively defined primary endpoints were device 
performance, skin and subcutaneous toxicities, efficacy out-
comes, and cosmetic outcome. The present report includes 68 
patients who have received treatment and have completed at 
least 1 month of follow-up. Six-month and 1-year follow-up 
data are available on 59 and 37 patients respectively.
The EBT device performed consistently, delivering the 
prescribed 34 Gy to all patients. In two fractions, 3.3 and 
3.5 Gy were delivered to one patient who received a total of 34 
Gy by the end of all 10 fractions. No technical issues occurred 
during placement or removal of the balloon   applicator other 
than the deflation of three balloons related to contact with 
sharp objects; the three balloons were replaced. Technical 
issues with the X-ray source or controller during treatment 
were infrequent (,3% of treatment visits) and were easily 
addressed.
Adverse events were collected during each patient visit. 
Reported adverse events were consistent with data from other 
studies of breast brachytherapy, although the rate of breast 
infection was very low (2.9%) in this EBT study. Studies with 
other forms of breast brachytherapy have reported infection 
rates of 4%–16%.26–30 Erythema, pruritis, and desquama-
tion typically resolved by the 6-month or 1-year follow-up 
visit, whereas the occurrence of breast tenderness, firmness, 
and seroma declined gradually. There have been no tumor 
recurrences reported as of the 6-month follow-up visit in 59 
patients and the 1-year follow-up visit in 37 patients.
Cosmetic outcomes were excellent or good in 83.9%–100% 
of evaluable patients at 1 month, 6 months, and 1 year. These 
outcomes are similar to those reported with other forms of 
breast brachytherapy. These cosmetic results are favorable 
compared with an earlier EBT study in which 44 patients 
were treated with EBT for early stage breast cancer.20 In the 
earlier study, cosmetic results were excellent or good in 75% 
of patients at the 1-year follow-up visit. Cosmetic results may 
be adversely affected by narrow skin bridges. In this study, 
the mean distance from balloon surface to skin surface was 
12.8 mm and ranged from 7.0 to 22.0 mm; in the previous 
study, the mean distance was nearly double (25.1 mm) and 
ranged from 8.0 to 96.0 mm, which does not explain the 
differences in cosmesis. This study showed an association 
between the rate of visible adverse events and cosmetic 
results; since this study appears to have a somewhat lower 
rate of Grade 2–3 adverse events as compared with the earlier 
study, the disparity in cosmetic results may be related to the 
specific adverse events reported in each study. The experi-
ence with EBT gained during the earlier trial informed the 
study design, training materials, and device instructions for 
this study and other EBT studies. In addition, the present trial 
utilized the next generation controller (Model 110), which 
may have provided some advantages over the controller 
(Model 100) utilized in the earlier study.
The risks associated with use of EBT include complica-
tions associated with the surgical implantation of the balloon 
applicator. Complications arising from the delivery of EBT 
appear to be similar to those resulting from other forms of 
breast irradiation, although dosimetric analyses from other 
studies demonstrate a reduced radiation dose to the heart and 
lung with EBT as compared with the same dose of breast 
Table 5 grade 2 and 3 adverse events. Adverse events that were 
possibly, probably, or definitely related to applicator placement 
or radiation therapy as reported at each follow-up visit
1 month 6 months 1 year
Grade 2 events
number of patients 68a 59 37
Induration/firmness 4 (5.9%) 3 (5.1%) 1 (2.7%)
erythema 4 (5.9%) 0 1 (2.7)d
seroma 1 (1.5%) 2 (3.4%)c 1 (2.7%)
rash/desquamation – moist 3 (4.4%)b 0 0
Breast tenderness 1 (1.5%) 1 (1.7%) 0
hypopigmentation 2 (2.9%) 0 0
Palpable mass 2 (2.9%) 0 0
Field contracture – slight  
indent in skin
0 0 1 (2.7%)
Field contracture – significant 0 1 (1.7%) 0
infection 1 (1.5%) 0 0
Grade 3 eventse
Field contracture – significant 1 (1.5%) 0 0
Fibrosis connective tissue 0 0 1 (2.7%)c
Notes:   aOne of the 69 treated patients did not complete the 1-month follow-up 
visit  due  to  an  acute  myocardial  infarction  and  subsequent  death;  no  treatment-
related  adverse  events  occurred  in  this  patient;  bincludes three unscheduled visits 
around 1 month post-treatment;  cincludes one unscheduled visit around 6 months 
post-treatment; dincludes one unscheduled visit around 1 year post-treatment; eOne 
patient had grade 3 diarrhea that was related to a Clostridium difficile infection due to 
a prophylactic antibiotic.OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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radiation from a radioisotope source.17,21 Dickler et al com-
pared dosimetric data from patients treated with 192Iridium-
based balloon brachytherapy (IrBT) with data from EBT 
treatment plans for the same patients. The mean ipsilateral 
lung dose (%V30) was 3.7% with IrBT as compared with 
1.1% with EBT (P , 0.05); the mean heart dose (%V5) 
was 59.2% with IrBT as compared with 9.4% with EBT 
(P , 0.05).17 Dosimetry was also reported by Mehta et al, 
in which patients treated with EBT had a mean ipsilateral 
lung dose (%V30) of 1.17 (± 1.15) and a mean heart dose 
(%V5) of 20.15 (± 18.48).20 Mille et al reported a dosimetric 
comparison of IrBT and EBT in a virtual patient with left-
side breast cancer and found that EBT resulted in a lower 
dose to healthy organ tissue (excluding ribs) than IrBT by a 
median dose reduction factor of 28.21 The clinical effects of 
a reduced dose to healthy tissue have not been fully evalu-
ated. The radiation dose and dose rate prescribed during this 
study were within the standard brachytherapy doses used in 
breast irradiation.
The potential benefits of EBT may include improved 
tumor control over surgery alone, shortened treatment time 
over whole breast irradiation, a reduction in the amount of 
radiation delivered to normal tissue as compared with whole 
breast irradiation and isotope-based balloon brachytherapy, 
and greater access to brachytherapy treatment facilities 
compared with isotope-based irradiation technologies, which 
require a specifically shielded radiation vault and HDR after-
loader unit. These study results are limited by the length of 
follow up, and longer follow-up data are needed.
Conclusion
One-year follow-up data from this observational, nonrandom-
ized, multicenter study demonstrate that this EBT device was 
reliable and well tolerated as an adjuvant radiation therapy 
for early stage breast cancer. Adverse events were consistent 
with those reported with radioisotope-based APBI.
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